29
Participants
Start Date
July 20, 2020
Primary Completion Date
January 12, 2024
Study Completion Date
February 27, 2024
MEN1611
MEN1611 oral dose administered twice daily for a continuous 28-day cycle.
Cetuximab
Cetuximab solution for infusion administered weekly via intravenous infusion.
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin
Azienda Ospedaliero Universitaria San Martino, Genoa
Istituto Clinico Humanitas, Rozzano
Istituto Europeo di Oncologia (IEO), Milan
Azienda Socio Sanitaria Territoriale Niguarda, Milan
Centre Georges François Leclerc, Dijon
Asklepios Klinik Altona, Hamburg
Hospital Universitario Ramon y Cajal, Madrid
Fundacion Jimenez Diaz, Madrid
Centro Integral Oncologico Clara Campal, Madrid
ICO - Site René Gauducheau, Saint-Herblain
Hospital Clinico Universitario de Valencia, Valencia
ICO - Site Paul Papin, Angers
Azienda Ospedaliero Universitaria Pisana, Pisa
Universitaetsklinikum Tuebingen, Tübingen
Klinikum der Universitaet Muenchen Campus Grosshadern, Munich
Klinikum rechts der Isar der TU, Munich
Mayo Clinic Arizona, Phoenix
The Oncology Institute of Hope and Innovation, Anaheim
MultiCare Health System Institute for Research and Innovation, Tacoma
Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden
Amsterdam University Medical Center, Amsterdam
Maastricht University Medical Center, Maastricht
Radboud Nijmegen, Nijmegen
Erasmus Medisch Centrum, Rotterdam
Examen sp. z o.o., Skórzewo
Centrum Onkologii-Instytut im.M.Sklodowskiej Curie, Warsaw
Hospital Universitari Vall d'Hebron, Barcelona
Lead Sponsor
Menarini Group
INDUSTRY